Clinical management of dyslipidaemia associated with combination antiretroviral therapy in HIV-infected patients.

Item

http://www.wikidata.org/entity/Q38723259

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Clinical management of dyslipi ...... rapy in HIV-infected patients.

@en

type

Item

label

Clinical management of dyslipi ...... rapy in HIV-infected patients.

@en

prefLabel

Clinical management of dyslipi ...... rapy in HIV-infected patients.

@en

P1476

Clinical management of dyslipi ...... rapy in HIV-infected patients.

@en

P2093

Isabella Bon

http://www.w3.org/2001/XMLSchema#string

Leonardo Calza

http://www.w3.org/2001/XMLSchema#string

Maria Carla Re

http://www.w3.org/2001/XMLSchema#string

Pierluigi Viale

http://www.w3.org/2001/XMLSchema#string

Roberto Manfredi

http://www.w3.org/2001/XMLSchema#string

Vincenzo Colangeli

http://www.w3.org/2001/XMLSchema#string

P2860

A randomized comparative trial of continued abacavir/lamivudine plus efavirenz or replacement with efavirenz/emtricitabine/tenofovir DF in hypercholesterolemic HIV-1 infected individuals

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

Cardiovascular risk prediction in HIV-infected patients: comparing the Framingham, atherosclerotic cardiovascular disease risk score (ASCVD), Systematic Coronary Risk Evaluation for the Netherlands (SCORE-NL) and Data Collection on Adverse Events of

Human immunodeficiency virus impairs reverse cholesterol transport from macrophages.

A phase IV, double-blind, multicentre, randomized, placebo-controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing central nervous system adverse events to etravirine.

The effect of a 12-week course of omega-3 polyunsaturated fatty acids on lipid parameters in hypertriglyceridemic adult HIV-infected patients undergoing HAART: a randomized, placebo-controlled pilot trial.

Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study.

Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study.

Effects of switching from efavirenz to raltegravir on endothelial function, bone mineral metabolism, inflammation, and renal function: a randomized, controlled trial.

Effects of switching from lopinavir/ritonavir to atazanavir/ritonavir on muscle glucose uptake and visceral fat in HIV-infected patients.

P304

1451-1465

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JAC/DKV494

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-02-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26846208

http://www.w3.org/2001/XMLSchema#string

P921

dyslipidemias